CAS 1801747-42-1

Formula: C16H19Cl2N5

InChI: InChI=1S/C16H19Cl2N5/c1-16(20)5-7-23(8-6-16)12-9-21-14(15(19)22-12)10-3-2-4-11(17)13(10)18/h2-4,9H,5-8,20H2,1H3,(H2,19,22)

InChI key: YGUFCDOEKKVKJK-UHFFFAOYSA-N

SMILES: CC1(CCN(CC1)C2=CN=C(C(=N2)N)C3=C(C(=CC=C3)Cl)Cl)N

2-Pyrazinamine, 6-(4-amino-4-methyl-1-piperidinyl)-3-(2,3-dichlorophenyl)-

CAS: 1801747-42-1

Formula: C₁₆H₁₉Cl₂N₅

Purity: 98%

Color and Shape: Solid

Molecular weight: 352.2616

Ref: IN-DA0021R0

SHP099

CAS: 1801747-42-1

SHP099

Formula: C₁₆H₁₉Cl₂N₅

Purity: ≥98%

Molecular weight: 352.26

Ref: 54-BUP11966

SHP099

CAS: 1801747-42-1

6-(4-Amino-4-methylpiperidin-1-yl)-3-(2,3-dichlorophenyl)pyrazin-2-amine

Formula: C₁₆H₁₉Cl₂N₅

Purity: 98%

Molecular weight: 352.26

Ref: IN-DG630472

SHP099

CAS: 1801747-42-1

SHP099 (SHP099 free base) free base is an effective, selective, orally bioavailable, and efficacious SHP2 inhibitor (IC50 =0.07 μM and p-ERK modulation in cells

Formula: C₁₆H₁₉Cl₂N₅

Purity: 98.73% - 99.4%

Color and Shape: Solid

Molecular weight: 352.26

Ref: TM-T3564

SHP099

CAS: 1801747-42-1

SHP099 is an allosteric inhibitor of the SHP2 protein, which is derived from targeted small-molecule drug development. Its mode of action involves binding to SHP2 in a region distinct from the catalytic site, thereby stabilizing the protein in its auto-inhibited conformation and preventing activation. This disrupts downstream signaling pathways mediated by SHP2, a protein-tyrosine phosphatase essential in promoting oncogenic signaling through the RAS/MAPK pathway.

Formula: C₁₆H₁₉Cl₂N₅

Purity: Min. 95%

Color and Shape: Powder

Molecular weight: 352.26 g/mol

Ref: 3D-BXC74742

6-(4-AMINO-4-METHYLPIPERIDIN-1-YL)-3-(2,3-DICHLOROPHENYL)PYRAZIN-2-AMINE

CAS: 1801747-42-1

Formula: C₁₆H₁₉Cl₂N₅

Purity: 98%

Color and Shape: Solid

Molecular weight: 352.26

Ref: 10-F544411